What Dyno Therapeutics does

Dyno Therapeutics is a privately held, venture-backed biotechnology company founded in 2018 that applies artificial intelligence and machine learning to design optimized adeno-associated virus (AAV) capsid delivery vectors for gene therapy. The company's foundational technology is the CapsidMap platform, which pairs high-throughput in vivo DNA multiplexing experimentation (producing billions of sequence-function data points per month) with ML-guided search algorithms to navigate capsid sequence space, supplemented by the LEAP (Low-shot Efficient Accelerated Performance) technology that generates out-of-distribution capsid variants. The company has launched nine AI-engineered capsids across three therapeutic areas: brain/CNS (Dyno-9zh, Dyno-yp2, Dyno-ahq, Dyno-hc9), muscle and neuromuscular (Dyno-bn8, Dyno-n96, Dyno-3hv), and eye (Dyno-4z2, Dyno-86m), with multiple capsids demonstrating 25x-280x performance improvements versus wild-type AAV9 in preclinical models.

Dyno operates a partnership-centric business model rather than developing its own therapeutics, commercializing its capsid platform through collaboration and license agreements with gene therapy developers including Roche, Astellas, Sarepta, Novartis, and NVIDIA. Revenue is generated through upfront payments, license exercise fees, research-phase payments, and clinical/regulatory/sales milestone payments, plus royalties on any commercialized products developed by partners using Dyno capsids. Cumulative disclosed deal value exceeds several billion dollars in potential milestones across all partnerships. In March 2026, Dyno extended its platform with Dyno Psi-Phi, a protein binder design suite comprising Dyno Phi (experimentally calibrated filters), Dyno Psi-1 (open-weight generative model trained on NVIDIA DGX Cloud), REST APIs at design.dynotx.com, and Claude Code Skills, broadening the company's scope beyond capsid engineering. The Dyno Frontiers Network, a curated ecosystem of 15 therapeutic developers, 7 manufacturers, 6 service providers, and 15 investor partners, supports developers with no-cost research access to capsids and downstream execution resources. The company is led by Cofounder and CEO Eric Kelsic, with cofounders from George Church's Harvard/Wyss lab including CSO Adrian Veres, VP ML Sam Sinai, and Executive Chairman Alan Crane.

Name

Dyno Therapeutics

Legal name

Dyno Therapeutics, Inc.

Website

https://dynotx.com

Company type

Private

Founded year

2018

Operating status

Operating

Headcount range

101–250 employees

Short description

Dyno Therapeutics designs AI-engineered AAV capsids for gene therapy through its CapsidMap platform, licensing optimized delivery vectors to therapeutic developers including Roche, Astellas, Sarepta, and Novartis.

Ownership category

akta.pro rank

Product category

AI-Designed AAV Gene Therapy Vectors

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)

SIC

Biological Products, (No Disgnostic Substances) (2836), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

AAV Vector Gene Therapy Developers (HLAAACAA)

akta.pro secondary industries

Gene Therapy for Rare/Monogenic Diseases (HLAAACAE), Neurology/CNS Gene Therapies (HLAAACAH), Cardiometabolic & Other Systemic Gene Therapies (HLAAACAI), Gene Therapy (Viral Vector/Plasmid) CDMO (HLAGABAE)

Keywords

• AI gene therapy
• AAV capsid design
• Viral vector engineering
• Protein binder design
• AI drug discovery

Headquarters

HQ city

Cambridge

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

1. Licensing and Milestone Payments from Therapeutic Partners: Revenue generated from collaboration and license agreements with gene therapy developers (Roche, Astellas, Sarepta, Novartis). Includes upfront cash payments, option/license exercise fees, research-phase payments, and clinical/regulatory/sales milestone payments tied to progression of partnered programs. Royalties on net sales of commercialized products are also received.
2. One-Time License Exercise Fees: Discrete payments when partners exercise options to license a specific capsid (e.g., $15M from Astellas in April 2026 for skeletal muscle capsid; $7M from Roche in January 2025 for neurological disease capsid).
3. Royalties on Net Sales: Ongoing royalty payments on worldwide net sales of any commercial products developed by partners using Dyno capsids.

Pricing tiers

Go-to-market motion4 records

Distribution channels5 records

Marketing channels8 records

Core offering

Dyno Therapeutics applies artificial intelligence and high-throughput in vivo experimentation to design optimized adeno-associated virus (AAV) capsid delivery vectors for gene therapy. The company designs, licenses, and partners AI-engineered capsids targeting the brain, muscle, and eye to gene therapy developers under collaboration and license agreements that include upfront fees, milestone payments, and royalties. Dyno also offers the Dyno Psi-Phi protein design suite, including open-weight generative models and APIs for protein binder design.

Product overview

Dyno Therapeutics operates a partnership-centric platform business built around its proprietary CapsidMap AI platform, which combines frontier AI models with high-throughput in vivo experimentation to design optimized AAV capsid delivery vectors. The core platform is enhanced by the LEAPSM (Low-shot Efficient Accelerated Performance) sub-technology. The company offers a portfolio of nine AI-engineered individual capsid products organized by tissue target: brain (Dyno-9zh, Dyno-yp2, Dyno-ahq, Dyno-hc9), muscle/neuromuscular (Dyno-bn8, Dyno-n96, Dyno-3hv), and eye (Dyno-4z2, Dyno-86m), each available for direct licensing. Building on the capsid platform, Dyno launched Dyno Psi-Phi, a generative protein binder design suite comprising Dyno Phi (filtering tools that predict real-world outcomes) and Dyno Psi-1 (an open-weight generative protein binder design model), all exposed through Dyno Psi-Phi REST APIs at design.dynotx.com and via Dyno Psi-Phi Claude Code Skills. The Dyno Frontiers Network program connects gene therapy developers with these capsids alongside manufacturing, service, and investor partners.

Differentiator

Problem solved

Functional benefit

Brands

• CapsidMap: Dyno's proprietary AI-powered platform for the design of novel adeno-associated virus (AAV) capsids for gene therapy, applying DNA library synthesis, next-generation DNA sequencing, and machine learning to measure and optimize in vivo gene delivery properties.
• LEAPSM (Low-shot Efficient Accelerated Performance)
• Dyno Psi-Phi
• Dyno Frontiers Network
• Genetic Agency Technology Conference (GATC)

Products and services

• Dyno Psi-Phi Suite of AI-powered protein design tools that includes Dyno Phi (filters predicting real-world experimental outcomes), Dyno Psi-1 (open-weight generative protein binder design model), Dyno Psi-Phi REST APIs, and Dyno Psi-Phi Claude Code Skills. Designed for therapeutic developers, computational biologists, and rare disease researchers to generate and evaluate protein binder designs programmatically.
• Dyno-9zh AI-engineered AAV capsid for CNS delivery that crosses the blood-brain barrier by binding the human Alkaline Phosphatase (ALPL) receptor, achieving up to 50% neuronal transduction in NHP cortex at 3e13 vg/kg with greater than 10x lower liver biodistribution than AAV9. Best-performing ALPL-targeting capsid when compared head-to-head in mouse and NHP.
• Dyno-yp2 TfR1-mediated AAV capsid for CNS delivery that binds the human transferrin receptor to cross the blood-brain barrier, achieving greater than 94% neuronal transduction in TfR-humanized mice with 113x higher brain transduction vs AAV9, 29x lower liver biodistribution than AAV9, and 80x lower liver biodistribution than BI-hTFR1.
• Dyno-ahq AAV capsid optimized for widespread IV delivery to the brain, reaching up to 30% of NHP neurons at 3e13 vg/kg with 280x higher brain transduction and 50x lower liver transduction vs AAV9. Engages a highly conserved candidate receptor supporting translation to humans.
• Dyno-hc9 (bCap 1) First Dyno capsid optimized for highly efficient delivery across the blood-brain barrier, achieving 100x higher brain transduction and 10x lower liver transduction vs AAV9, with broad CNS tropism reaching deep brain regions and spinal cord.
• Dyno-bn8 AAV capsid for skeletal and cardiac muscle delivery at IV doses as low as 5e12 vg/kg (25x lower than Elevidys), transducing 73-88% of myofibers in NHP skeletal muscles and 35-42% of cardiac cells. Compatible with AAV9-based manufacturing processes and licensed by Astellas in April 2026.
• Dyno-n96 AAVrh74-based AAV capsid for skeletal and cardiac muscle delivery at 5e12 vg/kg, transducing 74% of myofibers in NHP skeletal muscles with low liver biodistribution. Compatible with AAV9 and AAVrh74 production processes.
• Dyno-3hv First capsid optimized for highly efficient delivery to multiple tissues affected by neuromuscular disorders, including heart, skeletal muscle, and CNS. Transduces 50-90% of myofibers in NHP skeletal muscles at doses as low as 4e12 vg/kg.
• Dyno-4z2 AAV capsid optimized for highly efficient delivery to the retina through intravitreal injection, achieving greater than 40x retinal transduction vs AAV2 and 5x bipolar cell transduction vs an externally engineered reference capsid. Ideal for optogenetic gene therapies.
• Dyno-86m (eCap 1) First Dyno ocular capsid, optimized for highly efficient delivery to the retina through intravitreal injection with broad retinal tropism. Achieves 80x higher retinal transduction vs AAV2.

Quantifiable outcome

• Dyno-yp2 achieves 113x higher brain transduction vs AAV9 in humanized TfR1 mice at 2e13 vg/kg with 29x lower liver biodistribution than AAV9 and 80x lower than BI-hTFR1
• +9 more outcomes

Named customers18 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

Yes

API docs

API detail

Core technology

AI maturity

App detail

Integration3 records

AI capability6 records

Feature8 records

Partnerships

21 partnerships are on record, tiered secondary, major and flagship.

• Andelyn BiosciencessecondaryChannel Partner/ Reseller/ Distributor · 13 May 2026Manufacturing partner in the Dyno Frontiers Network with proven experience producing Dyno capsids.
• Cirsium BiosciencessecondaryChannel Partner/ Reseller/ Distributor · 13 May 2026Manufacturing partner in the Dyno Frontiers Network.
• Franklin BiolabssecondaryChannel Partner/ Reseller/ Distributor · 13 May 2026Manufacturing partner in the Dyno Frontiers Network.
• PackGenesecondaryChannel Partner/ Reseller/ Distributor · 13 May 2026Manufacturing partner in the Dyno Frontiers Network.
• RevvitysecondaryChannel Partner/ Reseller/ Distributor · 13 May 2026Manufacturing partner in the Dyno Frontiers Network.
• AldevronsecondaryImplementation/ SI/ Consulting Partner · 13 May 2026Service provider in the Dyno Frontiers Network.
• BioAnalysis LLCsecondaryImplementation/ SI/ Consulting Partner · 13 May 2026Service provider in the Dyno Frontiers Network.
• Charles River LaboratoriessecondaryImplementation/ SI/ Consulting Partner · 13 May 2026CRO partner in the Dyno Frontiers Network with expertise in AAV gene therapy and Dyno's platform.
• Curi BiosecondaryImplementation/ SI/ Consulting Partner · 13 May 2026Service provider in the Dyno Frontiers Network.
• Dark Horse Consulting GroupsecondaryImplementation/ SI/ Consulting Partner · 13 May 2026Regulatory consultant in the Dyno Frontiers Network with AAV gene therapy expertise.
• Eliquent Life SciencessecondaryImplementation/ SI/ Consulting Partner · 13 May 2026Regulatory consultant in the Dyno Frontiers Network with AAV gene therapy expertise.
• Y CombinatorsecondaryStrategic or Co-development Partner · 13 May 2026Startup accelerator partner in the Dyno Frontiers Network for companies incubating in Y Combinator.
• AnthropicmajorTechnology or Integration · 18 March 2026Anthropic integration: Dyno Psi-Phi is available as Claude Code Skills, providing authenticated access to Dyno's GPU-backed APIs directly within Anthropic's Claude Code. Dyno participated in beta testing of Anthropic's Claude Fable 5 model for AAV vector design.
• Trisk BiomajorStrategic or Co-development Partner · 11 November 2025Trisk Bio is the first manufacturing partner in Dyno's Frontiers Program, announced in November 2025 at GATC 2025. Trisk provides scalable, high-purity AAV production services for Dyno capsids, helping gene therapy developers reduce costs and accelerate development. Trisk has also onboarded the Dyno-yp2 capsid.
• 3PBioviansecondaryChannel Partner/ Reseller/ Distributor · 11 November 2025Manufacturing partner in the Dyno Frontiers Network providing AAV production services for Dyno capsids.
• NVIDIAflagshipTechnology or Integration · 9 May 2024NVIDIA and Dyno collaboration announced in May 2024 to leverage Dyno's AI and in vivo capabilities with NVIDIA's BioNeMo platform, NIM microservices, and accelerated computing for biological sequence design. The collaboration co-developed the open-source BioNeMo Framework (released November 2024). In March 2026, Dyno and NVIDIA jointly launched Dyno Psi-Phi at NVIDIA GTC 2026, including Dyno Psi-1 trained on NVIDIA DGX Cloud using Hopper GPUs and integration with NVIDIA Transformer Engine.
• Astellas PharmaflagshipStrategic or Co-development Partner · 1 December 2021Astellas entered a research collaboration with Dyno in December 2021 to develop next-generation AAV gene therapy vectors for skeletal and cardiac muscle. Dyno received $18M upfront and is eligible for milestone and royalty payments potentially exceeding $1.6B. In April 2026, Astellas exercised its option to license a Dyno capsid for skeletal muscle-targeted gene delivery ($15M license fee plus milestones and royalties), making Dyno the first company to license an AI-designed AAV capsid for both CNS and muscle gene therapies.
• RocheflagshipStrategic or Co-development Partner · 14 October 2020Roche entered into a collaboration and license agreement with Dyno in October 2020 to apply CapsidMap for CNS and liver-directed AAV gene therapies. Aggregate potential milestone payments may exceed $1.8B. In January 2025, Roche exercised an option to license a Dyno capsid for a neurological disease indication ($7M option fee plus up to $220M+ in milestones plus royalties). In October 2024, the companies entered a new $50M upfront CNS partnership with over $1B in potential milestones plus royalties. Roche is also building on Dyno's LEAP technology.
• Sarepta TherapeuticsmajorStrategic or Co-development Partner · 11 May 2020Sarepta and Dyno announced a partnership in May 2020 to develop next-generation AAV vectors for muscle diseases using Dyno's CapsidMap platform. Dyno could receive over $40M in upfront, option and license payments during the research phase, with additional significant future milestone payments and royalties on worldwide net sales. Partnership completed in 2025 with improved capsids developed.
• NovartismajorStrategic or Co-development Partner · 11 May 2020Novartis and Dyno announced an ocular collaboration in May 2020 to develop improved AAV vectors for gene therapies for ocular diseases. Financial terms include upfront consideration, research funding, license fees, clinical and sales milestone payments, and royalties. Partnership completed in 2024 with improved capsids developed.
• Harvard University / Wyss InstituteflagshipStrategic or Co-development Partner · 1 May 2018Dyno was founded in 2018 on technology developed in George Church's lab at the Wyss Institute for Biologically Inspired Engineering, Harvard Medical School. Dyno has an exclusive option to license the underlying technology from Harvard University, including IP around the comprehensive AAV capsid fitness landscape (Science 2019 publication). George Church, Tomas Bjorklund, and other Harvard scientists serve as Dyno cofounders or scientific advisors.

Scale indicators16 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• 4D Molecular Therapeutics: Clinical-stage gene therapy company engineering proprietary AAV capsids (e.g., 4D-150, 4D-710, 4D-175) for ophthalmology, pulmonology, and cardiology. Closest direct competitor to Dyno in machine-guided AAV capsid design, with multiple partnered and wholly-owned programs and similar deal structures.
• Affinia Therapeutics: AI-driven AAV capsid engineering company developing novel vectors for CNS, muscle, and cardiac indications. Builds engineered capsids using high-throughput data and computation, with similar partnership-plus-pipeline business model to Dyno.
• Voyager Therapeutics: Clinical-stage gene therapy company that has historically paired its TRACER-derived AAV capsid platform with pharma partners (e.g., Pfizer, Neurocrine, Novartis) for CNS indications. Direct comparability in capsid engineering + partnership model.

Broad incumbents

• REGENXBIO: Established AAV gene therapy platform company with proprietary NAV technology, extensive licensing business, and a wholly-owned clinical pipeline. Broader incumbent in AAV delivery, providing both licensed vectors (including to Roche, Novartis) and competing capsid IP.
• uniQure: Commercial-stage gene therapy company with AAV platform technology (HEMGENIX for hemophilia B) and a clinical pipeline in CNS and cardiovascular indications. Comparable gene therapy developer that uses and competes with various AAV capsid technologies.
• Pfizer (Internal Capsid Programs): Large pharma with significant internal AAV gene therapy programs (e.g., Beqvez for hemophilia B) and internal capsid engineering investments. Represents both a potential customer and a competitive threat to Dyno's partnership pipeline.
• Roche / Spark Therapeutics: Roche is Dyno's largest partner (>$3B in potential licensing deal value) and Spark is its gene therapy arm (Luxturna). They are simultaneously major customers and developers of competing gene therapy programs using Dyno and third-party capsids.

Emerging players

• Generate Biomedicines: AI-driven generative biology company designing novel protein therapeutics across multiple modalities. Overlapping AI-for-protein-design platform with Dyno Psi-Phi, though focused on therapeutic proteins rather than AAV delivery.

Others

• Crary Group / Deciduous Therapeutics (and similar AI-bio peers): Adjacent AI-driven biotech companies backed by Dyno's investor CRV. Representative of the broader AI-bio ecosystem in which Dyno operates and from which it sources investor, developer, and ecosystem partnerships through the Frontiers Network.
• Andelyn Biosciences: AAV-focused contract development and manufacturing organization (CDMO) and Dyno Frontiers Network manufacturing partner. Comparable ecosystem participant enabling gene therapy manufacturing, and a key distribution and production partner for Dyno's capsids.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks5 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/@Dyno_Tx/videos
• LinkedInlinkedin.com/company/dyno-therapeutics
• Xx.com/dyno_tx

Revenue estimate

Valuation estimate

Number of profiles

Profiles14 records

Funding overview

Funding rounds3 records

Investors9 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Dyno Therapeutics